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AbstrACt
Objectives Surgical site infection (SSI) complicates 
5% of all surgical procedures in the UK and is a major 
cause of postoperative morbidity and a substantial 
drain on healthcare resources. Little is known about 
the incidence of SSI and its consequences in women 
undergoing surgery for gynaecological cancer. Our 
aim was to perform the first national audit of SSI 
following gynaecological cancer surgery through 
the establishment of a UK-wide trainee-led research 
network.
Design and setting In a prospective audit, 
we collected data from all women undergoing 
laparotomy for suspected gynaecological cancer 
at 12 specialist oncology centres in the UK during 
an 8-week period in 2015. Clinicopathological data 
were collected, and wound complications and their 
sequelae were recorded during the 30 days following 
surgery.
results In total, 339 women underwent laparotomy 
for suspected gynaecological cancer during the study 
period. A clinical diagnosis of SSI was made in 54 
(16%) women. 33% (18/54) of women with SSI had 
prolonged hospital stays, and 11/37 (29%) had their 
adjuvant treatment delayed or cancelled. Multivariate 
analysis found body mass index (BMI) was the 
strongest risk factor for SSI (OR 1.08[95% CI 1.03 to 
1.14] per 1 kg/m2 increase in BMI [p=0.001]). Wound 
drains (OR 2.92[95% CI 1.41 to 6.04], p=0.004) 
and staple closure (OR 3.13[95% CI 1.50 to 6.56], 
p=0.002) were also associated with increased risk of 
SSI.
Conclusions SSI is common in women undergoing 
surgery for gynaecological cancer leading to delays 
in discharge and adjuvant treatment. Resultant delays 
in adjuvant treatment may impact cancer-specific 
survival rates. Modifiable factors, such as choice 
of wound closure material, offer opportunities for 
reducing SSI and reducing morbidity in these women. 
There is a clear need for new trials in SSI prevention 
in this patient group; our trainee-led initiative provides 
a platform for their successful completion.
IntrODuCtIOn  
Gynaecological cancers collectively account 
for 11% of all cancers affecting women in the 
UK. Surgery remains the mainstay of treat-
ment, and despite an increase in the use of 
minimally invasive techniques, a large propor-
tion of patients still require laparotomy. For 
many women, their treatment will involve a 
hysterectomy with an associated high risk of 
surgical site infection (SSI) due to the inher-
ently contaminated nature of procedures 
involving entry into the genital tract.
Although most women undergoing lapa-
rotomy can expect their wound to heal 
without any problem, there is a lack of high-
quality data in gynaecological oncology to 
strengths and limitations of this study
 ► This study documents real-world clinical practice 
in the prevention and management of surgical site 
infection (SSI) in women undergoing open gynaeco-
logical cancer surgery in the UK.
 ► Data were collected prospectively and consecutive-
ly without exclusions according to comorbidities or 
treatment from all women undergoing gynaecologi-
cal cancer surgery at 12 UK centres, encompassing 
the various national care settings (except Wales).
 ► Data relating to direct and indirect healthcare costs 
of SSIs were not available.
 ► Further longitudinal data examining the cancer-spe-
cific outcomes of this cohort are not currently 
available.
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indicate the incidence and consequences of SSI. A study 
by Iyer et al,1 which aimed to identify predictors of compli-
cations in women undergoing surgery for gynaecological 
malignancy, describes grade II-IV infections in 27.8% of 
all gynaecological surgery cases; accounting for 31% of all 
complications. Although this study identified predictors 
of complications, the consequences of such complica-
tions were not assessed. The need to identify preventable 
complications coupled with effective interventions 
remains. The importance of SSI prevention, across all 
surgical specialities, has also been acknowledged by the 
UK government with the publication of various national 
guidelines outlining care bundles with recommended 
interventions during the preoperative, intraoperative and 
postoperative phases of the patient journey.2 3 This has 
led to a downward trend in the incidence of SSIs in most 
types of surgery.4 However, worryingly, there has been a 
year-on-year rise in SSI related to abdominal hysterecto-
mies since 2014.4
Further research into the direct and indirect effects of SSI 
on the gynaecological oncology population and the addi-
tional interventions that could reduce SSIs is, therefore, 
urgently needed. An innovative UK-wide multicentre collab-
orative of trainees and consultants with an interest in clinical 
research in gynaecological oncology was established in 2015 
to develop and implement evidence-based interventions to 
improve surgical care for women undergoing gynaecolog-
ical cancer surgery.
The primary objective of this study was to define the 
incidence of SSI in the UK gynaecological oncology 
population undergoing laparotomy and record standard 
practices. The secondary objectives were to identify risk 
factors associated with infection and assess the potential 
impact on length of stay and delay to adjuvant cancer 
treatment. This study also aimed to provide baseline data 
to develop a modified enhanced recovery programme for 
women undergoing gynaecological cancer surgery.
MethODs
This prospective multicentre audit of all consecu-
tive women undergoing laparotomy for suspected or 
confirmed gynaecological malignancy was undertaken 
across 12 of the 44 UK tertiary centres during an 8-week 
period September–November 2015. Daily review of 
surgical cases was undertaken in each institute and cross 
referenced with theatre IT systems to ensure all subjects 
were included. Advice was sought from local ethics 
committees who confirmed that this study was exempt 
from ethical review as the research was limited to the 
secondary use of fully anonymised information previously 
collected in the course of normal care without the inten-
tion to use it for research at the time of collection.
Local audit leads were recruited via the British Gynae-
cological Cancer Society Trainees group and the Tomor-
rows Leaders in Surgical Research workshops. These local 
leads coordinated the prospective collection and coding 
of anonymised data using a standardised data collection 
tool developed in line with National Institute for Health 
and Care Excellence guidance.2 Additional information 
including patient demographics, comorbidities, surgi-
copathological and wound complication data were also 
contemporaneously collected. All patients were catego-
rised using the derived patient status risk index described 
by the American Society of Anesthesiologists (ASA).5 
Surgical complexity was classified using a modification of 
the surgical scoring system (online supplementary table 
A) developed by the Mayo Clinic6 for ovarian cancer. 
Each individual procedure was given a score, and the 
total score for the surgery was the sum of the individual 
scores. Surgeries were categorised into three groups of 
increasing complexity based on the overall score (low: 
score ≤3; intermediate: score 4–8; radical: ≥8). In addi-
tion to the procedure, the duration of surgery and esti-
mated blood loss were also recorded.
The Centres for Disease Control and Prevention (CDC) 
definitions for superficial incisional, deep incisional and 
organ/space SSI were used to standardise diagnosis of 
SSI across all centres (online supplementary table B).7 
A modified definition was applied for patient-reported 
SSI, as per the Public Health England Surgical Site Infec-
tion Surveillance programme protocol.8 The impact of 
SSI on length of stay, return to theatre, use of negative 
pressure wound therapy, admission to intensive care 
and time to adjuvant chemotherapy or radiotherapy was 
studied.
To ensure completeness of data and to capture events 
following discharge, all recorded interactions (ie, tele-
phone consultations/clinic visits/hospital records) with 
patients in the 30 days postoperatively were analysed. 
Data from patient reported infection following discharge 
as well as observed infection during admission were 
included in the analysis.
statistical analysis
Descriptive analysis of clinicopathological data were 
undertaken to characterise the cohort and the predictive 
value of each risk factor for SSI was separately assessed 
using univariable analysis by logistical regression or χ2 
as appropriate. The variables to include in the logistic 
regression were based on the univariate analysis and 
known risk factors for SSI. To take into account variations 
in the length of time to last recorded contact, the inci-
dence density was calculated using the number of cases 
in the numerator and the total number of days of patient 
follow-up (from inpatient surveillance) in the denomi-
nator giving the number of SSIs per 10 patient days of 
follow-up.
Patient involvement
No patients were directly involved in this research. However, 
the views of focus groups were sought regarding the most 
appropriate sequelae of SSI to measure. Patients are actively 
involved in the design of potential interventions to prevent 
SSIs and any future trials from our trainee-led initiative.
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results
Data collection
During the prospective study, undertaken between 1 
September 2015 and 1 November 2015, with follow-up 
until 1 December 2015, 12 UK tertiary centres submitted 
data for a total of 339 patients. Data were complete in 
98.0% of fields. Median time until last patient encounter 
was 22 days (IQR 14–41 days). The final patient contact in 
the postoperative follow-up period for most patients was 
at their outpatient review 4–6 weeks after surgery.
Participants
Baseline patient characteristics are shown in table 1. 
The median patient age was 62 years (IQR 53–71) with 
a median body mass index (BMI) of 28.0 kg/m2 (IQR 
24.0–32.8). Preoperative performance status varied with 
62 (18.3%) patients classified as ASA 1; 166 (49.0%) as 
ASA 2; and 87 (25.7%) as ASA 3. 13% of patients were 
hypoalbuminaemic (albumin <35 g/L).
The majority of surgeries were undertaken as primary 
treatments (244, 72%) with 69 (20.4%) patients under-
going interval surgery after neoadjuvant chemotherapy 
for ovarian cancer. Twenty-two (6.5%) patients under-
went surgery for recurrent disease with palliative intent 
(from all primary sites). Of the 339 study patients, 288 
(85.0%) had a diagnosis of cancer confirmed, the 
majority of whom, 200 (59%), had a diagnosis of ovarian 
cancer (table 1).
Infection prophylaxis
All patients were screened for methicillin-resistant Staphy-
lococcus aureus (MRSA) preoperatively, and colonisation 
with MRSA was confirmed in two patients who subse-
quently underwent preoperative eradication. Infection 
prophylaxis policy varied between centres with variations 
in surgical skin preparation and prophylactic antibiotics. 
A total of 318 out of 339 (93.8%) patients received intra-
venous antibiotics at induction of anaesthesia, of which 
292/318 (91.8%) was in line with local microbiology 
policy. Of those who received prophylactic intraoperative 
antibiotics, 23 (7.2%) received triple therapy, 85 (26.7%) 
received combined double therapy and 210 (66.0%) 
received single agent prophylaxis. The most frequently 
used antibiotic was co-amoxiclav, used alone or in combi-
nation in 236 (74.2%) patients. Three hundred and six 
(90.3%) surgeries were classified as clean contaminated 
or contaminated.
surgery
The majority of laparotomy incisions were midline and 
extended above the level of the umbilicus to the pubis. 
Median operating time was 150 min (IQR 110–191 min). 
The median surgical complexity score for the entire 
cohort was 2 (range 1–17, IQR 2–3) (table 1). Seven-
ty-four (21.8%) patients had a radicality score of ≥4, which 
included 50 (15.6%) patients who underwent bowel 
resection (table 1).
Table 1 Patient demographics
Characteristic
Cases (%) – unless 
otherwise stated
Age n=339
  Age (years), median (IQR) 62 (53–71)
BMI n=323
  BMI (kg/m2), median (IQR) 28.0 (24.0-32.8)
ASA n=315
  1 62 (18.3)
  2 166 (49.0)
  3 87 (25.7)
Comorbidity n=334
  Diabetes 34 (10.0)
  Oral hypoglycaemic/insulin use 21 (6.2)/13 (3.8)
  Thyroid dysfunction 43 (12.7)
  Immune defect 2 (0.6)
  Preoperative anaemia 34 (10.0)
  Coagulopathy 9 (2.7)
  Chronic kidney disease 15 (4.4)
  Chronic lung disease 37 (10.9)
  Current smoker 36 (10.6)
  Other non-active malignancy 16 (4.7)
Diagnosis n=337
  Ovarian/primary peritoneal cancer 200 (59.3)
  Endometrial cancer 61 (18.1)
  Cervical cancer 9 (2.7)
  Benign 51 (15.1)
  Other non-gynaecological cancer 16 (4.7)
FIGO stage n=325
  1 83 (25.5)
  2 23 (7.1)
  3 129 (39.7)
  4 24 (7.4)
  Not applicable 66 (20.3)
Surgical radicality n=338
  Standard (≤3) 265 (78.4)
  Intermediate (4–8) 61 (18.0)
  Ultraradical (≥8) 13 (3.8)
Procedure n=338
  Hysterectomy 272 (80.2)
  Oophorectomy/salpingectomy 305 (90.0)
  Omentectomy 250 (73.7)
  Pelvic lymph node dissection 67 (19.8)
  Para-aortic lymph node dissection 35 (10.3)
  Small bowel resection 19 (5.6)
  Large bowel resection 36 (10.6)
  Peritoneal stripping 55 (16.2)
Continued
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Postoperative wound management
Use of wound drains and skin closure techniques was 
highly variable and the incidence of drain use, skin 
closure and dressing used are shown in table 2. Dressing 
choice was largely dependent on National Health Service 
(NHS) site, with little variation within each institution.
surgical site infections
Of the 339 patients included in the study, 54 (15.9%) 
were diagnosed with an SSI by CDC criteria and 30 
(8.8%) had wound dehiscence. Twenty (5.9%) patients 
had dehiscence in the presence of infection. To take into 
account the variation in the length of follow-up, inci-
dence density was calculated; 0.5 cases of infection per 
10 days of patient follow-up was seen. Severity of infec-
tion was variable with the incidence of various markers of 
severity shown in table 3. Infection was most prevalent in 
patients undergoing laparotomy for endometrial cancer, 
with an incidence of 21.3% in this subgroup. However, 
there was no significant difference in incidence of SSI by 
site of tumour origin (p=0.7358).
Causative micro-organisms were isolated from wound 
culture in only 32/54 cases (59.3%). The most prevalent 
culture result showing mixed growth predominantly of 
Escherichia coli and/or other bowel commensals. Staphylo-
coccus aureus was a reported cause of SSI in four cases in 
this series.
The incidence of infection per cancer centre was vari-
able ranging from 6.3% to 41.2%. A funnel plot was 
constructed for each centre using the SSI incidence per 
centre (figure 1).
Further review of the centre that appears to be an 
outlier (figure 1, red triangle) demonstrates no evidence 
that the threshold for diagnosis of SSI was any lower at 
this centre. There was no excess of preoperative comor-
bidities in this subgroup of patients. However, there was 
a statistically significant difference in the radicality score 
of those with infection from this centre in comparison 
with the other 11 centres, with a mean score of 4.29 versus 
2.38, p=0.0194.
Predictors of ssI
Univariate analysis suggested that higher BMI, ASA, 
diabetes requiring insulin, use of a drain, choice of 
antiseptic for skin preparation and skin closure were 
associated with significant increase in SSI risk (p<0.05) 
(table 4). After accounting for other variables, higher BMI 
was associated with having a greater risk of infection, with 
the odds of infection increasing by on average 8% (95% 
CI 3% to 14%) for each extra unit of BMI. Insertion of a 
wound drain and wound closure with staples rather than 
suture were all associated with having an increased risk of 
infection (table 4). There was no evidence to suggest that 
ASA or using betadine rather than chlorhexidine skin 
preparation were associated with an increased infection 
rate, after taking into account the other variables.
sequelae
Median length of postoperative hospital stay was 5 days 
(range 1–71, IQR 4–8). In those that developed infection, 
there was clinical delay in discharge in 18/54 (33.3%). In 
the 37 patients with SSI who required adjuvant chemo-
therapy or radiotherapy, 11 (29.7%) experienced delay 
in commencing therapy directly or indirectly as a result 
of infection.
Approximately half of all infections were diagnosed 
following discharge and 5 (1.5%) patients necessitated 
readmission to hospital following diagnosis of infection. 
Thirty (55.6%) patients had evidence of skin dehiscence, 
14 of which required wound packing. As a result of wound 
complications, four patients returned to theatre, one 
patient was admitted to level 2/3 care and two patients 
required negative pressure wound therapy.
DIsCussIOn
Modelled on the highly successful trainee-led research 
collaboratives in other surgical specialties, the surgical 
gynaecological oncology research network was formed in 
2015 to address the paucity of clinical research in gynae-
cological cancer surgery. Our study provides a snapshot 
of current practice of the preoperative, intraoperative 
and postoperative prevention and management of SSI 
in women undergoing open gynaecological oncology 
surgery across the UK.
Characteristic
Cases (%) – unless 
otherwise stated
  Panniculectomy 3 (0.9)
  Colostomy 15 (4.4)
  Urostomy 2 (0.6)
ASA, American Society of Anesthesiologists, BMI, body mass 
index; FIGO, International Federation of Gynecology and 
Obstetrics.
Table 1 Continued 
Table 2 Postoperative wound management
Technique Usage n (%)
Missing 
data (n)
Intra-abdominal drain 59 17.4 7
Subcutaneous tissue closure 68 20.1 7
Local anaesthetic wound catheter 16 4.7 7
Skin closure Staples 174 51.3 0
Subcuticular 
monocryl
164 48.4
Other 1 0.3
Wound dressing Mepore 145 42.8 2
Tegaderm 68 20.1
Opsite 59 17.4
Other 63 18.6
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Our study demonstrates that SSI is highly prevalent 
within the gynaecological oncology population who 
undergo laparotomy with an incidence of 15.9%; 10 times 
higher than the incidence reported in the NHS Surgical 
Site Infection Surveillance Programme for women under-
going abdominal hysterectomy in 2015/2016.9 The high 
burden of complications is likely to reflect a combination 
of patient, surgical and disease-specific factors. Unsurpris-
ingly, infection is prevalent in patients with a high BMI, 
which perhaps explains the greater incidence observed 
in those within the endometrial cancer subgroup and 
in those with diabetes, given shared aetiological factors. 
Cancer and its treatments can result in immune defi-
ciency, increasing the risk of SSI in oncology patients. The 
contaminated nature and complexity of the procedures 
required in gynaecological oncology surgery further 
increase this risk.10
In a small proportion of patients, SSI is severe and/
or life threatening, necessitating return to theatre or 
advanced wound care and prolonged hospital stays. 
Our study provides evidence that SSI impacts on time 
to delivery of adjuvant cancer treatments in a significant 
proportion of patients. This has the potential to impact 
on response to treatment and overall cancer specific 
survival in these patients.10–12 Additional data, however, 
are needed to evaluate the impact of these delays on 
progression and mortality.
In this study, infection occurred in patients even where 
compliance with local infection prophylaxis standards 
were high. Analysis of the micro-organisms cultured 
from patients affected showed that E. coli and Entero-
bacter species predominated. This is in keeping with 
other studies of wound infection post hysterectomy13–15 
Table 3 Markers of surgical site infection (SSI) severity
Infection type and severity, n=54
Cases (%), unless 
otherwise stated
Infection Cultured organisms Positive culture 32 (59.3) 
Time of infection Postoperative admission 24 (44.4)
Community 25 (46.3)
Local hospital readmission 4 (7.4)
Central hospital readmission 1 (1.9)
Antibiotic route Intravenous 24 (44.4)
Oral 25 (46.3)
None 6 (11.1)
Length of course Days, median (range) 7 (5–14)
Severity Fever Temperature >38°C 11 (20.4)
WCC ×10/L, median (IQR) 10 (7–14)
Cellulitis Clinical diagnosis 24 (44.4)
Skin dehiscence Clinical diagnosis 30 (55.6)
Treated with packing 14 (25.9)
Managed without packing 16 (29.6)
Sheath dehiscence 1 (1.9)
Intensive care unit/High 
dependency unit admission
1 (1.9)
Negative pressure wound therapy 2 (3.7)
Return to theatre 4 (7.4)
WCC, white cell count.
Figure 1 Funnel plot of surgical site infection (SSI) by UK 
cancer centre: funnel plot of the number of reported SSIs for 
each gynaecological cancer unit versus effective sample size 
for each unit. The funnels correspond to 95% confidence 
limits (dashed lines). The outlier unit is denoted by a triangle, 
while units with SSI incidence within the 95% confidence 
limits are marked with a circle.
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and the vaginal flora of our, predominately, postmeno-
pausal cohort.16 Previous studies have determined that up 
to 15% of cultured organisms may be resistant to broad 
spectrum combinations of antibiotics.15 In our study, 
sensitivities of the microorganisms cultured from affected 
patients were not readily available. Further studies would 
be required to determine whether resistance to current 
antibiotic regimens could explain the high prevalence of 
SSI in this population.
The use of drains and staples for wound closure was 
positively associated with SSI in our population. These 
devices are commonly used in patients thought to be at 
high risk of SSI, and therefore, the associations seen in this 
study may not be causative. Surgical drains are often used 
to drain body fluids away from a dead space to promote 
wound healing and prevent potential SSI. Although there 
is conflicting data as to whether the drains are associated 
with an increase in SSI, no studies have shown a reduction 
in SSI following the use of surgical drains.17–20 Judicious 
use of drains and timely removal is therefore indicated. 
Staples are an efficient way to close a linear incision and 
may be preferred by some surgeons after particularly long 
or technically difficult cases. Various randomised control 
studies and subsequent meta-analyses fail to show that the 
use of sutures over staples resulted in any difference in 
SSI in gynaecological surgery.21–25
At a time when many NHS trusts are keen to invest in 
enhanced recovery programmes to encourage a speedy 
and proactive approach to recovery for patients, this 
audit demonstrates a need for effective management of 
wounds to minimise the incidence of wound infection 
and provide effective management rapidly when it does 
Table 4 Predictors of SSI
Univariate logistic regression
Type of risk factor Variable OR (95% CI) P value
Non-modifiable 
prior to surgery
BMI (per kg/m2) 1.09 (1.04 to 1.13) <0.001
Age (per year) 1.01 (0.99 to 1.04) 0.236
ASA three or more (vs less than three or missing) 1.73 (0.93 to 3.22) 0.083
Albumin (per g/L) 0.98 (0.93 to 1.02) 0.309
FIGO stage (per unit) 1.05 (0.76 to 1.45) 0.773
Diabetic requiring insulin (vs not requiring insulin for glycaemic control) 5.00 (1.61 to 15.5) 0.005
Neoadjuvant chemotherapy (vs none) 0.50 (0.22 to 1.17) 0.110
Cancer type
  Endometrium (vs ovarian) 1.48 (0.72 to 3.04) 0.291
  Benign (vs ovarian) 0.68 (0.08 to 5.64) 0.722
  Cervical (vs ovarian) 0.87 (0.36 to 2.10) 0.752
  Other (vs ovarian) 0.73 (0.16 to 3.34) 0.682
Non-modifiable 
surgical risk factor
Surgical radicality score (per unit) 1.02 (0.89 to 1.19) 0.718
Clean contaminated (vs clean) 2.26 (0.67 to 7.66) 0.189
Incision site
  Above umbilicus (vs transverse) 1.64 (0.36 to 7.39) 0.519
  Below umbilicus (vs transverse) 2.15 (0.46 to 10.19) 0.333
Modifiable at time 
of surgery
Chlorhexadine skin preparation (vs betadine) 0.54 (0.30 to 0.97) 0.039
Wound drain (vs none) 3.23 (1.68 to 6.19) <0.001
Subcutaneous fat stitch (vs none) 1.50 (0.76 to 2.95) 0.245
Staples (vs subcuticular suture) 3.58 (1.84 to 6.97) <0.001
Prophylactic postoperative antibiotics (vs none/missing) 1.69 (0.86 to 3.31) 0.126
Multivariate logistic regression
Non-modifiable 
prior to surgery
BMI (per kg/m2) 1.08 (1.03 to 1.14) 0.001
ASA (per unit) 1.01 (0.48 to 2.11) 0.989
Diabetic requiring insulin (vs not requiring insulin for glycaemic control) 3.34 (0.90 to 12.39) 0.071
Modifiable at time 
of surgery
Chlorhexadine (vs betadine) 0.58 (0.30 to 1.134) 0.109
Drain (vs none) 2.92 (1.41 to 6.04) 0.004
Staples (vs subcuticular suture) 3.13 (1.50 to 6.56) 0.002
ASA, American Society of Anesthesiologists; BMI, body mass index; SSI, surgical site infection.
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occur. These data support the development of a stratified 
care bundle to reduce delay to adjuvant treatment asso-
ciated with SSI focusing on women with high BMI and 
poorly controlled diabetes.
strengths and limitations
To the best of our knowledge, this study is the first to 
comprehensively review current practice surrounding 
the prevention and management of SSI in open gynae-
cological cancer surgery. The United Kingdom Gynaeco-
logical Oncology Surgical Outcomes and Complications 
(UKGOSOC) study found a slightly lower wound compli-
cation rate of 9.6% across all types of gynaecological 
cancer surgery in ten UK gynaecological cancer centres.1 
However, this study included patients undergoing both 
laparoscopic and open surgery. Laparoscopic surgery has 
previously been shown to have lower incidence of post-
operative complications such as wound infection.26–28 
We have, therefore, chosen to examine care practices in 
women undergoing open surgery specifically.
The strength of our review of practice is that the data were 
prospectively collected using standardised data collection 
forms at 12 participating centres from around the UK. 
As this was a review of practice, data from all consecutive 
surgeries were included as patient recruitment was not 
required. We included all classes of SSI (including super-
ficial incisional infections) and their sequelae; thus, not 
presupposing, that particular classes of SSI would have an 
impact on patient recovery and subsequent cancer treat-
ment. Despite our use of a standardised proforma and 
the use of a preagreed definition of SSI, there remained 
a potential for variation in its interpretation from site to 
site. This may have contributed to the outlier unit with 
the disproportionately high rate of SSI. However, this type 
of variation is likely to also reflect that seen in day-to-day 
practice. Twelve of the 44 units that offer tertiary level 
gynaecological cancer surgery participated in this review. 
No units from the South West or Wales participated. The 
inclusion of these units together with a longer data collec-
tion window may have led to a larger sample, allowing the 
identification of further potential risk factors for SSI and 
highlighting additional practices that may reduce wound 
infection rates. The identification of risk factors and good 
practice points will enable us to develop a tool to person-
alise patient care plans with the aim of reducing SSI.
COnClusIOns
This trainee-led collaborative initiative demonstrates the 
need to determine whether addressing modifiable risk 
factors can prevent SSI in gynaecological cancer surgery. 
Ultimately, a reduction in delayed discharge and subse-
quent delays in the commencement of adjuvant treat-
ment could result in improved patient outcomes.
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